HitGen has entered into a drug discovery research collaboration with Boehringer Ingelheim to identify novel small molecule leads for targets of interest. 

Under the agreement, HitGen will use its technology platform, based on DNA-encoded library design, synthesis, and screening, to discover the leads for Boehringer Ingelheim. HitGen will receive upfront payments, and will also be eligible for milestone payments from Boehringer Ingelheim. 

“This collaboration further emphasizes the role of HitGen in the rapidly developing field of DNA-encoded chemistry. We will work closely with Boehringer Ingelheim scientists to generate new lead compounds for their research programmes to address unmet medical needs.” said Dr. Jin Li, chairman and chief executive officer of HitGen.